Should You Buy Entrada Therapeutics Inc (TRDA) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Entrada Therapeutics Inc (TRDA) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish momentum, the lack of positive news, insider selling activity, and weak financial performance make it prudent to hold off on investing right now.
Technical Analysis
The technical indicators show a bullish trend with MACD histogram at 0.0836 (positive and expanding), RSI_6 at 63.885 (neutral zone), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of R1: 11.855, with a pivot at 10.766.
Analyst Ratings and Price Target Trends
Roth Capital recently lowered its price target from $17 to $13 while maintaining a Buy rating, reflecting broader market sentiment and competition in the pipeline. The company’s key pipeline updates are expected in 2026, which is a long-term horizon.
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.5 USD with a low forecast of 13 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.5 USD with a low forecast of 13 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 11.660
Current: 11.660
